ATCC AND BIOAGILYTIX ANNOUNCE PARTNERSHIP TO DEVELOP CUSTOM CELL-BASED ASSAY SOLUTIONS TO SUPPORT BIOPHARMACEUTICAL R&D

Combined expertise will create best-in-class assay systems for drug potency, stability testing and other applications

MANASSAS, Va. and DURHAM, N.C. — ATCC, a global leader in biological materials development, management and standards, and BioAgilytix, a leading provider of contract testing services with a specialization in biologics, today announced a strategic partnership to develop new and custom cell-based assays to accelerate and enhance biopharmaceutical research and development.

The partnership combines ATCC’s deep expertise in developing, authenticating, banking, and provisioning cells with BioAgilytix’s world-class capabilities in the development, validation and execution of cell-based assays. Under the agreement, ATCC will offer tool and reagent development and storage services, including custom-engineered cell lines and primary cells, as a complement to the broad array of assay solutions offered by BioAgilytix. Assays will include those used to establish the potency and stability of

< | >